Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYuanfeng ZhangJSJingrui Sui

Discussion

Loading...

Member takes

Overview

Clinical data reveals low-dose ATG and PTCY may reduce GVHD incidence in patients undergoing allo-HSCT, suggesting improved safety.

Key Points

  • This research aimed to evaluate the effectiveness and safety of low-dose ATG combined with fractionated low-dose PTCY for preventing GVHD after allo-HSCT.
  • Retrospective analysis of clinical data from 29 patients undergoing allo-HSCT
  • Regimen included low-dose ATG, fractionated low-dose PTCY, cyclosporine, and mycophenolate mofetil
  • Patient population included AML, MDS, ALL, MPAL cases, with haploidentical and unrelated donor transplants
  • At D+100, the incidence of grade I–IV acute GVHD was 8.4%
  • One-year overall survival rate was 77.3% and progression-free survival rate was 62.5%
  • Incidence of bloodstream infection was 13.8% and hemorrhagic cystitis was 10.3%

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d03dhttps://doi.org/10.1182/blood-2025-7737
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation2025 · 7 citations
  2. 2Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  3. 3Impact of the addition of antithymocyte globulin to post‐transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post‐transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation2025 · 5 citations
  4. 4Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  5. 5Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation2025 · 1 citations